Montelukast as disease modifying treatment for Parkinson’s disease: a pilot study.
Objective: To assess safety and tolerability of high dose Montelukast as a possible disease modifying treatment for Parkinson’s disease. Background: Emerging evidence suggests that the…Preliminary Report on the efficacy of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson’s disease: Phase IIa double-blind, randomized controlled trial.
Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) delivered intravenously to slow the progression of…Preliminary Report on the Safety and Tolerability of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for Parkinson’s disease: Phase IIa double-blind, randomized controlled trial
Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) purified from bone marrow-derived from a healthy…Parkinson’s Disease and Chronic Inflammatory Demyelinating Polyneuropathy: Broadening the Clinical Spectrum of VCP Mutations?
Objective: Valosin-containing protein (VCP) mutation causes a multiorgan disease characterized by inclusion body myopathy, Paget disease and frontotemporal dementia, more rarely by Charcot-Marie-Tooth disease type…Baseline fluid biomarkers in a phase 2 clinical trial in Parkinson’s Disease
Objective: To evaluate baseline CSF and blood-based biomarkers of pathology in early-stage Parkinson’s Disease (PD) participants in the phase 2 clinical trial PASADENA. Background: Observational…GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson’s disease.
Objective: To investigate the effect of the structurally targeted allosteric regulator GT-02287 on rotenone-induced neurotoxic effects in a Parkinson’s disease animal model. Background: Mutations in…Axial impairment and bradykinesia are related to increased CSF sTREM2, a neuroinflammation biomarker, in Parkinson’s disease
Objective: To explore the association between Parkinson’s disease (PD) motor symptoms and CSF biomarkers for neuroinflammation and neurodegeneration. Background: Previous in vivo and post mortem…Evaluation of neuroprotective role of carvacrol via Nrf2-NLRP3 axis in rotenone induced PD mice model
Objective: To explore the antioxidant and anti-inflammatory role of Carvacrol via Nrf2-NLRP3 axis in rotenone induced PD mice model Background: NLRP3 inflammasome mediated neuroinflammation is…RNA editing contributes to the inflammatory astrocytic response in Parkinson’s disease.
Objective: 1) Using an IPSC derived cell model to explore astrocytic responses alone and cocultured neurons to alpha-synuclein oligomer (αsynO) treatment.2) Determine the extent to…The Role of Adaptive Immunity caused by α-synuclein Recognition Specific Sequence Peptide on the Onset of Parkinson’s Disease Pathogenesis
Objective: We investigated whether α-synuclein-derived peptides (recognized specific sequence in α-synuclein) can drive T-cell response and evaluated the neurotoxicity of α-synuclein peptide-specific T-cell in Parkinson’s…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 22
- Next Page »